Although response rates to Trastuzumab-based chemotherapy of HER2-overexpressing breast cancers can exceed 50%5, the vast majority of patients will eventually experience disease progression, despite ongoing Trastuzumab therapy3. Here, ERBB2 is linked to breast carcinoma.